Conditions: Hepatitis C
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 173
Healthy volunteers: no

Brief summary:
To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection

Detailed description:

Arms:
arm 1: Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks arm 2: Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks

Interventions: intervention 1: Daclatasvir intervention 2: Sofosbuvir
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: